Affiliation:
1. From the Department of Medical Oncology and Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, and Cancer Research Campaign, Drug Development Office, Cambridge Terrace, London, United Kingdom, and Department of Oncology, Waikato Hospital, Hamilton, and Department of Clinical Oncology, Auckland Hospital and Auckland Radiology Group, Auckland, New Zealand.
Abstract
PURPOSE: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) causes vascular shutdown in preclinical models. Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies were performed in the phase I trials to examine changes related to blood flow and permeability in tumor and muscle. PATIENTS AND METHODS: Sixteen patients treated with DMXAA from 500 to 4,900 mg/m2 had DCE-MRI examinations before and after treatment. The maximum gradient, the maximum enhancement, and the area under the signal-intensity–time curve (AUC) over the first 90 seconds were calculated for each pixel in regions of interest (ROIs) in muscle and tumor, and the median value for each ROI was obtained. Changes after treatment were compared with 95% limits of agreement for an individual and for groups using data from our reproducibility study. RESULTS: Nine of 16 patients had significant reductions in AUC 24 hours after the first dose of DMXAA, and eight of 11 patients had reductions of up to 66% in AUC 24 hours after the last dose. Mean reductions in gradient, enhancement, and AUC were 25%, 18%, and 31%, respectively, 24 hours after the last dose, significantly greater than the 95% limits of change for a group of 11 patients. Enhancement and AUC in muscle 24 hours after the first dose were significantly reduced, but no significant changes were seen 24 hours after the last dose. CONCLUSION: DMXAA significantly reduces DCE-MRI parameters related to tumor blood flow, over a wide dose range, consistent with the reported tumor vascular targeting activity. Further clinical evaluation of DMXAA is warranted.
Publisher
American Society of Clinical Oncology (ASCO)
Reference58 articles.
1. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid
2. Zwi LJ, Baguley BC, Gavin JB, et al: Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79,1994-85,
3. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo
4. Plowman J, Narayanan VL, Dykes D, et al: Flavone acetic acid: A novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631,1986-635,
5. Bibby MC, Double JA, Phillips RM, et al: Experimental anti-tumor effects of flavone acetic acid (LM975). Prog Clin Biol Res 280: 243,1988-246,
Cited by
140 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献